@article{3020566,
    title = "PCSK9 Antibody-based treatment strategies for patients with statin intolerance",
    author = "Voutyritsa, E. and Damaskos, C. and Farmaki, P. and Kyriakos, G. and Diamantis, E. and Quiles-Sanchez, L.V. and Garmpi, A. and Garmpis, N. and Patsouras, A. and Stelianidi, A. and Savvanis, S.",
    journal = "In vivo (Athens, Greece)",
    year = "2021",
    volume = "35",
    number = "1",
    pages = "61-68",
    publisher = "International Institute of Anticancer Research",
    doi = "10.21873/INVIVO.12232",
    keywords = "alirocumab;  evolocumab;  ezetimibe;  fenofibrate;  human monoclonal antibody;  hydroxymethylglutaryl coenzyme A reductase inhibitor;  hypocholesterolemic agent;  low density lipoprotein cholesterol;  proprotein convertase 9;  proprotein convertase 9 inhibitor;  unclassified drug;  hydroxymethylglutaryl coenzyme A reductase inhibitor;  hypocholesterolemic agent;  monoclonal antibody;  PCSK9 protein, human;  proprotein convertase 9;  subtilisin, cholesterol blood level;  drug efficacy;  drug hypersensitivity;  drug safety;  drug utilization review;  human;  hypercholesterolemia;  muscle disease;  Review, Antibodies, Monoclonal, Humanized;  Anticholesteremic Agents;  Humans;  Hydroxymethylglutaryl-CoA Reductase Inhibitors;  Proprotein Convertase 9;  Subtilisin",
    abstract = "Background: Statin intolerance refers to the inability of a patient to tolerate statin therapy, presenting muscle aches, pains, weakness and muscle inflammation. Thus, numerous patients are not treated with suitable statinbased therapy or take only very low doses. As a result, the desired decrease in low-density lipoprotein cholesterol (LDLC) is not achieved, resulting in patients at a high risk for cardiovascular events, requiring an alternative lipidlowering treatment. Common treatments manage to reduce the LDL-C level by up to 20%. Recently, new alternative treatment options have been proved to lower the LDL-C level by up to 70%. These treatment strategies are based on human monoclonal antibodies against protein convertase subtilisin/kexin 9 (PCSK9). Materials and Methods: Herein, we review the efficiency of anti-PCSK9 in treatment of hypercholesterolemic patients with statin intolerance. We focused on the use of PCSK9 inhibitors in statin-intolerant patients and we estimated the clinical results concerning the reduction of the mean LDL-C concentration and the side effects that were observed. Results: In the majority of cases, treatment strategy based on PCSK9 was successful and achieved the end-points. Conclusion: PCSK9 inhibition can be considered as a treatment of option for lipid-lowering in statin-intolerant patients. © 2021 International Institute of Anticancer Research. All rights reserved."
}